Safety and Efficacy of ALX-0600 in Subjects With Active Crohn's Disease Who Completed Protocol CL0600-008
Crohn's Disease
About this trial
This is an interventional treatment trial for Crohn's Disease focused on measuring Crohn Disease, Crohn's Disease
Eligibility Criteria
Inclusion Criteria: Subjects must have completed participation in the Pilot Active Crohn's Disease Study. Subjects must continue to meet all inclusion criteria for Pilot Active Crohn's Disease Study with the following exceptions: CDAI score greater than 220 Stool samples not required C-reactive protein levels are not an exclusion criterion Exclusion Criteria: Subject must continue to meet all exclusion criteria for Pilot Active Crohn's Disease Study with the following exceptions: Participation in a clinical study of an experimental drug or device within 30 days before signing consent.
Sites / Locations
- Advanced Clinical Therapeutics
- Rocky Mountain Gastroenterology
- Rx Trials
- Clinical Trials Management of Boca Raton
- Clinical Research of West Florida
- Venture Research
- Pinnacle Trials
- Saint Joseph's Health System
- Northwestern University School of Medicine
- University of Chicago
- University of Louisville
- Long Island Clinical Research Associates
- Asher Kornbluth, MD, PC
- Wake Research Associates
- Cleveland Clinic Foundation
- Lynn Health Science Institute
- Atilla Ertan
- University of Utah
- McGuire DVAMC
- Dean Foundation Research Center
- Vancouver General Hospital
- Health Sciences Center
- Queen Elizabeth II Health Sciences
- Life Screening Centres
Arms of the Study
Arm 1
Experimental
1
All subjects in the study dosed at 0.1 mg/kg teduglutide